Drug intelligence / Profile preview

DES-7987

Development stage: Unknown
Lead developer: D. E. Shaw Research
Modality: Small Molecules

Overview

DES-7987 is a small molecule drug developed by D.E. Shaw Research. It acts as a blocker of the intermediate conductance calcium-activated potassium channel protein 4 (KCNN4), also known as KCa3.1. By inhibiting KCNN4, DES-7987 modulates potassium ion flow in cells, which can impact various physiological processes related to immune system function, nervous system activity, and cardiovascular health. The drug is being investigated for potential therapeutic use in diseases such as asthma, ischemic stroke, and pulmonary fibrosis[1][3].

Targets

KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)

Beyond the preview

Go deeper on DES-7987.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DES-7987.

Explore the full profile